|
Gene: FBLN7 |
Gene summary for FBLN7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FBLN7 | Gene ID | 129804 |
Gene name | fibulin 7 | |
Gene Alias | TM14 | |
Cytomap | 2q13-q14.1 | |
Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | Q53RD9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
129804 | FBLN7 | ATC09 | Human | Thyroid | ATC | 4.87e-03 | 1.31e-01 | 0.2871 |
129804 | FBLN7 | ATC12 | Human | Thyroid | ATC | 3.88e-30 | 6.53e-01 | 0.34 |
129804 | FBLN7 | ATC1 | Human | Thyroid | ATC | 1.19e-03 | 1.58e-01 | 0.2878 |
129804 | FBLN7 | ATC4 | Human | Thyroid | ATC | 3.69e-36 | 8.14e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:01101492 | Thyroid | ATC | regulation of biomineralization | 45/6293 | 99/18723 | 9.34e-03 | 3.44e-02 | 45 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBLN7 | SNV | Missense_Mutation | c.267N>A | p.Asp89Glu | p.D89E | Q53RD9 | protein_coding | deleterious(0.01) | benign(0.392) | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FBLN7 | insertion | Nonsense_Mutation | novel | c.1107_1108insTTCCACAAGACCCTCTTTCCAAATGATTAAGGAAA | p.Ser370PhefsTer10 | p.S370Ffs*10 | Q53RD9 | protein_coding | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
FBLN7 | deletion | Frame_Shift_Del | novel | c.1060delC | p.Leu354SerfsTer32 | p.L354Sfs*32 | Q53RD9 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
FBLN7 | SNV | Missense_Mutation | novel | c.1283N>T | p.Ser428Phe | p.S428F | Q53RD9 | protein_coding | tolerated(0.21) | benign(0.111) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FBLN7 | SNV | Missense_Mutation | novel | c.949N>A | p.Gln317Lys | p.Q317K | Q53RD9 | protein_coding | tolerated(0.05) | probably_damaging(0.992) | TCGA-AA-3952-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
FBLN7 | SNV | Missense_Mutation | rs569662326 | c.779G>A | p.Arg260Gln | p.R260Q | Q53RD9 | protein_coding | tolerated(0.58) | benign(0.001) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBLN7 | SNV | Missense_Mutation | rs369700908 | c.727N>A | p.Ala243Thr | p.A243T | Q53RD9 | protein_coding | tolerated(0.61) | benign(0.001) | TCGA-AD-6548-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FBLN7 | SNV | Missense_Mutation | rs747179865 | c.377N>T | p.Thr126Ile | p.T126I | Q53RD9 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FBLN7 | SNV | Missense_Mutation | rs749054176 | c.1279N>A | p.Val427Met | p.V427M | Q53RD9 | protein_coding | deleterious(0.02) | possibly_damaging(0.605) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
FBLN7 | SNV | Missense_Mutation | c.1139G>A | p.Ser380Asn | p.S380N | Q53RD9 | protein_coding | tolerated(0.16) | benign(0.035) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |